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Summary     
 
Liver fibrogenesis is a dynamic and highly integrated molecular, tissue and cellular process 
that during the course of a chronic liver disease (CLD) leads progressively to an excess deposition 
of extracellular matrix (ECM) components in an attempt to limit the consequences of chronic 
parenchymal injury. Irrespective of etiology, liver fibrogenesis is sustained and modulated by an 
intense cross talk occurring between different hepatic cell populations that involves the synthesis 
and release of several mediators including growth factors, cytokines, chemokines, reactive oxygen 
species, adipokines, vasoactive agents and plasma proteins. In this scenario a major pro-fibrogenic 
role is played by a heterogeneous population of α-smooth muscle actin (α-SMA) positive cells 
defined as hepatic myofibroblasts (MFs). Hepatic MFs are highly proliferative and contractile cells, 
primarily responsible for excess deposition of ECM components and involved in ECM altered 
remodeling observed in CLDs. MFs also represents a unique and critical cellular crossroad able to 
integrate incoming paracrine or autocrine signals, released from all hepatic cell populations 
involved or available in the microenvironment, as well as to synthetize and release mediators 
which sustain and perpetuate fibrogenesis, chronic inflammatory response and neo-angiogenesis. 
This review has been designed to offer critical knowledge on hepatic MFs including terminology, 
essential definitions and characterization of MFs, with a focus on the origin of these cells (mainly 
from hepatic stellate cells and portal fibroblasts or, to a less extent, bone marrow-derived cells), 
the process of activation and the functional responses that these cells can afford in the fibrogenic 
progression of CLDs.     
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1.   Liver fibrogenesis in the scenario of chronic liver diseases  
1.1 Introductory remarks and definitions  
Chronic liver diseases (CLD) are characterized by persisting parenchymal (i.e.,  hepatocyte) 
injury  that is induced by a limited and well defined number of etiological agents or conditions. On 
a worldwide basis,  according to the respective clinical relevance, chronic liver injury can be 
elicited by:  i) chronic infection by hepatitis B and C viruses, ii) chronic exposure to altered 
metabolic  conditions (non-alcoholic fatty liver disease or NAFLD), iii) chronic exposure to drug or 
toxins (with excess alcohol consumption being predominant in western countries),  iv)  
autoimmune-mediated injury (mainly primary biliary cirrhosis or PBC and primary sclerosing 
cholangitis or PSC) or  v) inherited defects (hereditary hemochromatosis, Wilson’s disease).  
Persisting liver parenchymal injury then results in chronic activation of inflammatory and wound 
healing response that, together with other mechanisms (oxidative stress, derangement of 
epithelial-mesenchymal interactions and, possibly, epithelial to mesenchymal transition or EMT, 
reviewed in Novo et al., 2014), can sustain the process of liver fibrogenesis, now recognized as the 
major driving force for excess deposition of extracellular matrix (ECM) components and fibrotic 
scar formation (i.e., liver fibrosis, the net tissue result) (Friedman, 2008a,2008b; Parola et al., 
2008; Dranoff and Wells, 2010; Povero et al., 2010; Forbes and Parola, 2011; Zhang and Friedman, 
2012; Mallat and Lotersztajn, 2013; Novo et al., 2014; Marra and Tacke, 2014).     
 Liver fibrogenesis as a process should be then defined as a dynamic and highly integrated 
molecular, tissue and cellular process that during the course of a CLD leads to a progressive excess 
accumulation of ECM components in an attempt to limit the consequences of chronic 
parenchymal injury (Friedman, 2008; Parola et al., 2008; Parola and Forbes, 2012; Novo et al. 
2014). Irrespective of the etiology, liver fibrogenesis is then critical for the progression of any form 
of CLD eventually leading to liver cirrhosis and hepatic failure (Friedman, 2008; Parola et al., 2008; 
Parola and Forbes, 2012; Rosselli et al., 2013; Novo et al. 2014). According to this definition of liver 
fibrogenesis, cirrhosis can be then defined as an advanced stage of CLD, characterized by the 
formation of regenerative nodules of parenchyma surrounded and separated by fibrotic septa, 
and associated with significant changes in organ vascular architecture, development of portal 
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hypertension and major related complications such as variceal bleeding, hepatic encephalopathy, 
ascites and hepatorenal syndrome as well as an increased risk of developing hepatocellular 
carcinoma (HCC) (Friedman, 2008; Parola et al., 2008; Parola and Forbes, 2012; Rosselli et al., 
2013; Novo et al. 2014).  
1.2 Liver fibrogenesis in the progression of chronic liver diseases 
 According to introductory remarks and basic definitions one can rationally envisage liver 
fibrogenesis  as a major pathophysiological event driving the progression of CLDs, irrespective of 
etiology.  Indeed, as suggested in Figure 1, liver fibrogenesis and of course chronic liver injury and 
persistent inflammatory response, are intrinsically correlated and span throughout the entire 
natural history of any CLDs, being fundamental for the other pathophysiological events to occur 
and for the effective progression of the disease (Friedman, 2008; Parola et al., 2008; Forbes and 
Parola, 2012; Rosselli et al., 2013; Novo et al. 2014). Along these lines, chronic activation of 
inflammation and the recruitment and activation of cells of either innate or acquired immunity is 
seen to progressively result in a pro-fibrogenic environment characterized by the significant 
synthesis and release of several mediators, including growth factors, cytokines, chemokines, 
adipokines, ROS and others. This environment is critical for the impairment of liver 
regeneration/hyperplasia observed in the progression of CLDs and is believed to favor persistent 
activation of MF-like cells, chronic activation of wound healing as well as excess deposition of ECM 
components, the latter event being usually paralleled by altered or inefficient ECM remodeling. 
The transition from the early stage of chronic injury and significant fibrosis towards a more 
advanced condition of CLD is then believed to involve hypoxia and angiogenesis. Indeed these two 
events are suggested to drive both fibrogenesis and the progressive development of vascular 
changes that will accompany CLD development through the conditions of pre-cirrhosis (Figure 1).   
Although liver fibrosis in the early stage and likely in the pre-cirrhosis one is potentially reversible 
(i.e., following the removal of chronic exposure to the specific etiology or to effective therapy), 
with the time deposition of ECM components becomes more and more significant.  Fibrotic septa 
and strictly related vascular changes then start to significantly modify the overall structure of liver 
parenchyma leading to the classic histopathological features of cirrhosis and the related ensue of 
portal hypertension and related pathophysiological events. As recently suggested, from a clinical 
point of view cirrhosis does not simply represent the end-point of a defined CLD and at least two 
distinct stages of cirrhosis should be distinguished  (Rosselli et al., 2013):  i) compensated cirrhosis, 
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characterized by the lack of overt clinical manifestations and by a hepatic vein pressure gradient 
(HVPG) within the 5–10 mmHg range; ii) decompensated cirrhosis, this time characterized by overt 
clinical manifestations and HVPG values > 10–12 mmHg and, along with the risk to develop HCC,  
to eventually enter in the stage of liver failure and the disease becoming then systemic.  
Epidemiological data that have unequivocally outlined the highly significant worldwide clinical 
impact of CLDs and HCC  (recently summarized in Novo et al., 2014) can then only emphasize  the 
relevance of persistent liver fibrogenesis in the overall scenario of progressive CLDs.    
1.3 Cell populations in liver fibrogenesis 
 Liver fibrogenesis, irrespective of etiology, can be considered as a process which is 
sustained and modulated by an intense cross talk occurring between different hepatic cell 
populations that involved the synthesis and release of several mediators, including growth factors, 
cytokines, chemokines, adipokines, ROS and vasoactive agents and plasma proteins. Any resident 
liver cell population, that may also respond to plasma proteins and to conditions of tissue hypoxia,  
has been described to significantly contribute to liver fibrogenesis during chronic liver injury and 
CLD progression (Friedman, 2008a, 2008b; Parola et al., 2008; Dranoff and Wells, 2010; Forbes and 
Parola, 2011; Parola and Marra, 2011; Zhang and Friedman, 2012; Iwaisako et al., 2012; Mallat and 
Lotersztain, 2013; Novo et al., 2014). In such a scenario of pro-fibrogenic environment (see Figure 
2) injured hepatocytes represent during CLD progression a major source of ROS and of other 
redox-related mediators or reactive intermediates as well as the most relevant source (in 
quantitative terms) of vascular endothelial growth factor (VEGF), particularly in the presence of 
hypoxic areas. Parenchymal cell damage and death (either necrotic or apoptotic) will of course 
sustain the chronic activation of inflammatory response which mainly involves macrophages 
obtained from resident Kupffer cells as well as from monocytes recruited from peripheral blood 
and of bone marrow origin.  Activated macrophages sustain liver fibrogenesis by synthetizing and 
releasing a huge number of pro-fibrogenic and pro-inflammatory mediators. As shown in Figure 2, 
the list of macrophage-derived mediators includes at least ROS, transforming growth factor β1 
(TGFβ1), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), the pro-
inflammatory primary cytokines interleuchin-1 (IL-1) and tumor necrosis factor α (TNFα) as well as 
several chemokines with monocyte chemoattractant protein-1  (MCP-1 or CCL2) playing a major 
role in modulating the response by several liver cell populations (Marra and Tacke, 2014).  
Although not cited in Figure 2, the reader should note that other cells of the innate immunity like 
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natural killer T (NKT)-cells can modulate liver fibrogenesis (Novo et al., 2014). Liver sinusoidal 
endothelial cells, when damaged and /or activated during chronic liver injury, can contribute to 
the overall pro-fibrogenic scenario by synthetizing and releasing specific mediators like nitric oxide 
(NO), endothelins  (ETs), insulin-like growth factor 1 (IGF1) and prostaglandins (PGs) in addition to 
other already cited like ROS, PDGF, TGFβ1, IL-1 and  bFGF. Even platelets have been reported to 
contribute to this scenario of cell-cell interactions by releasing PDGF,  TGFβ1, IGF1 as well as 
epidermal growth factor (EGF), transforming growth factor α (TGFα) and tromboxanes. 
         If one refer to the ability of release mediators (Figure 2), liver fibrogenesis is of course 
significantly sustained by hepatic myofibroblasts or MFs, to which this review is specifically 
dedicated. Details concerning origin, process of activation and role in fibrogenesis will be 
described starting from next section. Here it is sufficient to remark that these MFs are both target 
for mediators generated and/or released by other liver cells as well as active source of mediators 
acting in a paracrine/autocrine way.   
 
2. Hepatic Myofibroblasts    
2.1 Hepatic Myofibroblasts: what in a definition 
For a liver - dedicated pathologist the term “hepatic myofibroblast” is a very familial one 
that apply to an apparently heterogeneous population of cells that share a mesenchymal-like 
ultrastructural phenotype, express α-smooth muscle actin (α-SMA, the most reliable marker for 
these cells) and/or other mesenchymal-like markers and are easily identified by 
immunohistochemistry in fibrotic and cirrhotic human liver specimens (Cassiman et al., 2001; 
Friedman, 2008a; Parola et al., 2008; Dranoff and Wells, 2010).  Although activated hepatic MFs 
are likely to represent a rather heterogeneous population of cells in relation to their origin (see 
later), current literature emphasizes their major role in sustaining fibrogenic progression of any 
CLD, irrespective of their origin and of specific etiology (Friedman, 2008b; Parola et al., 2008; 
Forbes and Parola, 2011; Rosselli et al., 2013; Novo et al. 2014). Indeed, hepatic MFs are currently 
envisaged as highly proliferative and contractile cells able to contribute to liver fibrogenesis and 
CLD progression by displaying a number of phenotypic responses. Hepatic MFs are primarily 
responsible for excess deposition of ECM components but, in their activated state,  also play a 
critical role in the altered remodeling of ECM which typically characterizes any progressive CLDs.  
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Moreover, liver MFs operate also through the critical synthesis and paracrine/autocrine release of 
several growth factors and mediators that are able to sustain and perpetuate not only fibrogenesis 
but also chronic inflammatory responses and neo-angiogenesis. As recently pointed out (see 
Figure 2), the central role of MFs as effectors of fibrogenesis,  is emphasized by their intrinsic 
ability to act as unique and critical cellular crossroad that, in the overall scenario of a progressive 
CLD, can integrate incoming paracrine or autocrine signals (including growth factors, pro-
inflammatory cytokines, chemokines, proangiogenic mediators, adipokines, ROS and others) 
released from all hepatic cell populations involved and/or available in the microenvironment 
(Novo et al., 2014).            
 According to current literature, liver fibrogenesis in progressive CLDs has been proposed to 
be sustained by at least four main pro-fibrogenic mechanisms: i) chronic activation of the wound 
healing response, which is likely the most relevant mechanism from a general point of view for 
CLDs and that is believed to predominate in CLDs by hepatotropic viruses (HBV and HCV) as well as 
in CLD with autoimmune etiology; ii) oxidative stress, again a general mechanism intimately 
related to chronic liver injury that has been reported as predominant mechanism in CLDs by 
chronic alcohol consumption or altered metabolism (NAFLD/NASH - related CLD); iii) a 
derangement of epithelial-mesenchymal interactions, which is usually detected in the frame of 
chronic cholangiopathies; iv) epithelial to mesenchymal transition (EMT) of either hepatocytes or 
cholangiocytes, although this mechanism is still controversial and highly debated (Pinzani and 
Rombouts, 2004; Parola et al., 2008; Forbes and Parola, 2011; Novo et al., 2014).  In addition to 
these major mechanisms, other mechanisms have emerged in the last decade that may 
significantly affect fibrogenic CLD progression and include the involvement of: i) hypoxia, hypoxia-
inducible factors (HIFs) and angiogenesis, as well as ii) of inflammasomes as pro-inflammatory and 
pro-fibrogenic determinants; iii) adipokines which have a relevant role particularly in CLD 
associated to metabolic disturbances (metabolic syndrome and/or obesity and type 2 diabetes);  
iv) the process of autophagy and v) the role of natural killer and natural killer-T cells (the reader 
interested in pro-fibrogenic mechanisms can refer to a recent review  by Novo et al., 2014).  
More than a decade ago Cassiman et al. (2002) have proposed the possibility to recognize, 
irrespective of aetiology and according to their antigen profile and tissue localization, at least four 
different subpopulations of MFs in pathological human specimens obtained from patients affected 
by CLDs: i) portal MFs, which are MFs detected in the expanded connective tissue around portal 
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tracts; ii) septal MFs, which are detected in the inner part of fibrotic septa; it should be noted that 
portal MFs and  septal MFs share a common strong positivity for α-SMA as well as a more variable 
positivity to other antigens like glial fibrillary acidic protein (GFAP), brain-derived nerve growth 
factor (BDNF) and α-B-crystallin (ABCRYS); iii) interface MFs that are, by definition, α-SMA positive 
cells detected at the edge between fibrotic septa and the surrounding parenchyma (i.e., where 
active fibrogenesis usually occurs); interface MFs express more intense stain for GFAP and ABCRYS 
as well a variable degree of positivity for other antigens like, in addition to BDNF, also  neuronal 
cell adhesion molecule (N-CAM), neuronal growth factor (NGF) and neurotrophin 4 (NT-4);  iv) 
activated, myofibroblast - like, hepatic stellate cells (HSC/MFs),  which are α-SMA-positive that are 
easily recognized first by their localization in or around capillarised sinusoids of fibrotic/cirrhotic 
livers and as cells within pseudolobules; these cells, originating mainly from 
activation/transdifferentiation of hepatic stellate cells (HSC), are strongly positive for α-SMA ad N-
CAM, very positive for GFAP, NGF,  BDNF, NT-3 and synaptophysin (SYN) as well as significantly 
positive for other antigens like NT-4, ABCRYS, p75 and the NT receptors tyrosine kinase (Trk) A and 
B.  On the basis of localization and antigen repertoire Cassiman et al. (2002) at that time proposed 
that, apart from HSC/MFs likely deriving mainly from HSC,  portal MFs (and possibly  septal MFs) 
may originate from portal fibroblasts whereas the origin of interface MFs was supposed to be 
more heterogeneous. Although this overall morphological interpretation has progressively 
changed with the advent of more powerful technologies for fate tracing and the availability of 
specific transgenic mice, terms like portal MFs, interface MFs and HSC/MFs  are still widely used 
and easy to understand for any pathologist, basic scientist or clinician. On the other hand, one 
should recall that within the antigen repertoire displayed by HSC/MFs and by other types of MFs 
(Geerts, 2001; Cassiman et al., 2002)  one can find several proteins usually associated to cells of 
neural origin, including GFAP, P75 and nestin. This led to the hypothesis that HSC may originate 
from neural crest during embryogenesis, rapidly abandoned following one of the pioneer attempt 
made to trace the origin of this peculiar cell type by employing Wnt1Cre and Rosa26 reporter mice 
(Cassiman et al., 2006), opening the way to the search for mesenchymal origin of HSC and of other 
cells reported to trans-differentiate into MFs.     
2.2. The embryonal origin of mesenchymal cells able to give rise to liver MFs 
 Extensive literature data indicate that although HSCs are widely recognized as the most 
relevant source of MFs, indeed α-SMA positive profibrogenic MF-like cells have been shown to 
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originate from different cell sources during the progression of CLDs (Friedman, 2008a,2008b; 
Parola et al., 2008; Dranoff and Wells, 2010; Povero et al., 2010; Forbes and Parola, 2011; Asahina, 
2012; Zhang and Friedman, 2012; ; Iwaisako et al., 2012; Mallat and Lotersztajn, 2013; Novo et al., 
2014; Wells, 2014). The heterogenous origin of MFs is, in turn,  somewhat intrinsically related to 
the complexity of the scenario concerning the origin of different mesenchymal cell types in the 
developing liver. According to a series of nice experimental studies by Asahina and coworkers 
(Asahina et al., 2009,2011,2012) as well as by other laboratories (Hoppo et al., 2004; Kubota et al., 
2007; Suzuki et al., 2008) we have now a consistent knowledge of the different liver mesenchymal 
cell types in developing murine  liver and of how these cells can differentiate in those reported to 
be able to be activated to a MF-like phenotype.  As summarized in Figure 3, the origin of the cells 
having the potential to be activated into MFs is in the developing murine liver represented by the 
septum transversum mesenchyme (STM).  As it is well known, in mice liver bud forms from the 
foregut endoderm at approximately embryonic day (E) 9. At that time the STM which surrounds 
both the foregut endoderm and cardiac mesoderm starts to secrete fibroblast growth factors 
(FGFs) and bone morphogenetic proteins (BMPs) as a relevant step to induce differentiation from 
endoderm of hepatoblasts, the bi-potent progenitor cells able to differentiate into both 
hepatocytes and biliary epithelial cells (Zaret, 2002). The liver bud in mice embryos is formed at 
E9.5 to E10.5 from hepatoblasts budding that leaving the foregut endoderm invade the 
surrounding STM (Enzan et al., 1997). However, elegant studies that employed MesP1Cre and 
Rosa26lacZ reporter mice  in order to follow cells of mesoderm origin have shown that,  before the 
formation of liver bud, the STM is formed by MesP1 positive mesoderm (Asahina et al., 2011). Still 
before formation of liver bud the STM also express specifically Wilm’s tumor 1 (Wt1), a protein 
that later in the development is expressed only by mesothelial and sub-mesothelial cells. By using 
Wt1CreERT2 and Rosa26 reporter mice,  Asahina and coworkers (2009, 2011) were able to label 
STM cells and to trace this cell lineage. Data indicate that these STM cells gives rise to both 
mesothelial cells (positive for activated leukocyte cell adhesion molecule or ALCAM, WT1 and 
podoplanin) and submesothelial cells, which express ALCAM and WT1 but also desmin and 
p75NTR. These cells are the most likely source of either HSCs, which are positive for WT1, desmin 
and p75NTR, as well as for the so-defined perivascular mesenchymal cells (PMCs). PMCs, which 
are positive for desmin, Jagged 1, p75NTR and α-SMA, are the cells proposed to give rise to portal 
fibroblasts, smooth muscle cells and the few fibroblasts detected around the central vein. This has 
been reported to happen in mouse embryos at E 10-13.   As also shown in Figure 3,  HSCs and 
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PMCs may also derive directly from WT1 positive STM cells but the most critical point here is that 
two of the most relevant mesenchymal cell types described to undergo activation/trans-
differentiation into MF-like cells (HSCs and portal fibroblasts) have then a common origin from 
MesP1 positive mesoderm.   
 
2.3 The adult cells that can give rise to hepatic MFs 
As previously recalled, hepatic MFs represent a rather the heterogeneous population of α-
SMA positive cells. As we will see in detail in the next sections, literature data indicate that hepatic 
MFs originate mainly from HSCs or portal fibroblasts through a process defined as of 
activation/trans-differentiation. Such a process leads to the appearance of a highly proliferative, 
migratory and contractile MF-like phenotype able to synthetize excess ECM components as well as 
and to remodel the extracellular matrix and to sustain angiogenesis and/or inflammatory 
response, also offering a contribute in modulating immune response (Friedman, 2008a, 2008b; 
Parola et al., 2008; Dranoff and Wells, 2010; Forbes and Parola, 2011; Zhang and Friedman, 2012; ; 
Iwaisako et al., 2012; Mallat and Lotersztain, 2013; Novo et al., 2014; Wells, 2014). Although most 
of present knowledge on liver MFs has been originated from studies performed on HSC/MFs it is 
generally accepted that major phenotypic responses of liver MFs may be shared also by MFs 
originating from portal MFs (with some exception for these cells) as well as, possibly, from other 
sources such as mainly cells recruited into the chronically injured liver from bone marrow like 
fibrocytes and mesenchymal stem cells or MSCs (Forbes and Parola, 2011).  The next sections then 
offer an overview of  major informations and concepts on the cells that can give rise to liver MFs. 
According to literature data, a section will be also dedicated to the controversial and highly 
debated hypothesis that at least some of the pro-fibrogenic cells in CLD  progression may originate 
from either hepatocytes or cholangiocytes following a process of epithelial to mesenchymal 
transition (EMT).   
 
3. Hepatic stellate cells and the process of activation/transdifferentiation into liver MFs  
3.1 HSCs in normal liver or quiescent HSCs 
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 Hepatic stellate cells (HSCs) are perisinusoidal cells that in the normal liver reside in the 
subendothelial space of Disse and are characterized by the presence of cytoplasmic processes 
defined as intersinusoidal (or interparenchymal) and subendothelial. These cytoplasmic processes 
allow these cells to establish contacts with a relevant number of hepatocytes as well as of liver 
sinusoidal endothelial cells (LSECs) but also with adjacent HSCs and nerve endings (Wake, 1980; 
Geerts, 2001). Under physiological conditions (or quiescent state) HSCs have been reported to play 
at least three major roles that are either lost or deregulated in CLD  (Geerts, 2001; Friedman, 
2008b): i) HSCs are responsible for intrahepatic uptake, storage and release of vitamin A and 
retinoids which are typically retained within lipid droplets in the perinuclear cytoplasm; this 
function is progressively lost during CLD when the cells acquire the MF-like phenotype;   ii) HSCs 
have a role, together with LSEC and hepatocytes, in the synthesis and deposition in the space of 
Disse  of basal membrane like – ECM components (mainly collagen type III, collagen type IV and 
laminin) as well as in the remodeling of such extracellular matrix on the basis of their ability to 
produce several metalloproteinases (mainly MMP1, MMP2 and, to a less extent, MMP3, MMP10, 
MMP13 and MMP14) and related tissue inhibitors (TIMP1 and TIMP2);  under conditions of CLD 
this function in HSC/MFs is dramatically deregulated to favor excess deposition of ECM 
components versus remodeling;  iii) HSCs have been proposed to act as ‘liver specific pericytes’ 
able to regulate sinusoidal blood flow by responding to vasoactive peptides (mainly ET-1 and NO) 
and neurotransmitters of the autonomous nervous system (ANS); this function, which is favored 
by the intimate contact established by HSCs with LSECs and by the axons of ANS with HSCs, is 
somewhat exacerbated during the progression of CLD.       
 A fourth additional role has been suggested more recently for HSCs that are now envisaged 
as cells able also to contribute significantly to hepatic development and regeneration (reviewed in 
Yin et al., 2013).  Along these lines, HSCs are believed to contribute to vessel formation and 
integrity through their intimate cross-talk with LSECs based on the ability of HSCs to secrete the 
chemokine SDF1 and to express PDGF β receptor whereas LSECs produce PDGFβ and the SDF1 
receptor CXCR4, with SDF1 reported to also facilitate the recruitment of hematopoietic stem cells 
in the liver.   HSCs have been reported to also stimulate the proliferation of hepatoblast progenitor 
cells and hepatocytes through the release of hepatocyte growth factor (HGF), Wnt, fibroblast 
growth factor (FGF), and retinoic acid (Yin et al., 2013). HSCs may also modulate the differentiation 
of hepatoblast into hepatocytes or cholangiocytes through the control of  ECM composition within 
the liver as well as, at least in CLDs, to drive the differentiation of hepatic progenitor cells into 
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cholangiocytes through the release of the Notch ligand jagged 1 (Jag1) (Boulter et al., 2012).  
 It should be noted that HSCs have been also proposed as putative progenitors of epithelial 
cells in the liver (Yang et al., 2008; Michelotti et al., 2013) but this hypothesis was not confirmed 
by a successive fate-tracing experimental study (Mederacke et al., 2013).            
 
 
3.2 The process of activation / transdifferentiation of HSCs into MF-like cells (HSC/MFs)  
 HSC/MFs (i.e., activated myofibroblast-like cells originated from HSCs) have been 
historically the first pro-fibrogenic cells identified in either experimental and clinical conditions. 
These cells have been extensively investigated in the past two decades and represent the cell 
population for which the process of activation and profibrogenic mechanisms are best 
characterised  (Friedman, 2008b; Forbes and Parola, 2012; Mallat and Lotersztajn, 2013; Novo et 
al., 2014). HSC/MFs are still believed to be the most relevant pro-fibrogenic cells by most 
laboratories involved in liver fibrogenesis and this view has been recently reinforced by an elegant 
fate tracing experimental study  that, by employing a novel Cre-transgenic mouse able to label 
99% of HSCs, showed that as much as 82-96% of liver MFs originated directly from HSCs 
(Mederacke et al., 2013) in murine models of toxic, cholestatic and fatty liver disease.    
 Extensive literature data support the notion that  quiescent HSCs,  in conditions of chronic 
liver injury, undergo a peculiar process of activation/trans-differentiation which involves 
significant changes in their morphology and the induction of pro-fibrogenic phenotypic responses 
that are indeed very close to those observed in human or rodent HSCs when cultured on plastic 
substrate (Friedman, 2008b; Parola et al., 2008; Forbes and Parola, 2012; Mallat and Lotersztajn, 
2013; Novo et al., 2014). This process of activation has been described to proceed in sequential 
stages of initiation and perpetuation (Friedman 2008a,2008b)(Figure 4). The step of initiation 
represents an early response which is stimulated by several paracrine signals that leads HSCs to 
evolve in a  transient, potentially reversible, contractile and pro-fibrogenic cellular phenotype.   
This transient phenotype  is characterised by a rapid induction of PDGFβ receptor expression and 
is potentially primed  to respond, in conditions of chronic liver injury, to all those growth factors 
and mediators (see specifically section 3.3 as well as Figure 2 and Figure 4) that are critical in 
sustaining the phenotypic responses operated by fully activated MF-like phenotype (i.e., 
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perpetuation) (Friedman, 2008b; Parola et al., 2008; Forbes and Parola, 2012; Mallat and 
Lotersztajn, 2013; Novo et al., 2014).  Of course, if liver injury is acute, resolution of tissue injury  
that follows activation of inflammatory response and conventional wound healing would result in 
the progressive disappearance of mediators and the recovery of normal microenvironment 
conditions,  leading eventually to either apoptotic cell death of transiently activated cells or to 
their reversion to a quiescent phenotype. As we will see later, induction of apoptosis of transiently 
activated cells may require the intervention of restorative macrophages as well as of NKT cells.  
3.3 The functional responses of HSC/MFs: a paradigm for the multiple role of hepatic MFs 
 Once fully activated by pro-fibrogenic mediators and by conditions related to the 
chronically injured tissue microenvironment, HSC/MFs have been described to operate a number 
of phenotypical responses or functions that may serve as a paradigm for the entire population of 
hepatic MF-like cells (summarized in Figure 4). Indeed, one should take in mind that most of 
present knowledge on liver MFs comes directly from studies investigating properties of human as 
well as rodent (murine and rat) HSC/MFs (Friedman, 2008b; Parola et al., 2008; Forbes and Parola, 
2012; Mallat and Lotersztajn, 2013; Novo et al., 2014). Accordingly, one should also takes into 
account the widely acknowledged issue that HSC/MFs can operate during CLD progression so-
defined paracrine-autocrine loops (i.e. synthetizing and releasing mediators for whom these cells 
also express cognate receptors). This has been characterized mainly for HSC/MFs and for 
mediators like TGFβ1, PDGF-BB, MCP-1 or CCL2, ET-1 and VEGF. Phenotypic responses or pro-
fibrogenic properties of HSC/MFs will be synthetically described in the following sub-sections by 
focusing the attention to the mediators and related receptors involved.    
3.3.1 HSC/MFs as rapidly proliferating cells. HSC/MFs are by definition a cell population 
characterized by an impressive proliferative attitude. These cells proliferate,  display typically 
enhanced survival and then migrate and accumulate in response to paracrine/autocrine effects of 
several growth factors, cytokines, lipid mediators, or adipokines produced by the injured liver or 
profibrogenic environment. Proliferation of HSC/MFs, in particular, is elicited by a number of 
mitogens, including PDGF, basic fibroblast growth factor (bFGF), Angiotensin II,  VEGF and 
thrombin (Pinzani and Marra, 2001; Friedman, 2008a; Parola et al., 2008; Forbes and Parola, 2012; 
Mallat and Lotersztajn, 2013), with PDGF isoforms (particularly PDGF-BB) considered as the most 
potent and effective mitogenic stimuli. PDGF-BB has been shown to be released by activated 
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kupffer cells, sinusoidal endothelial cells and platelets but a very significant contribution (i.e., 
during active fibrogenesis) in the synthesis and release of this mediator is by activated HSC/MFs 
themselves in an autocrine/paracrine pathway.   
3.3.2 HSC/MFs as cells able to migrate. A critical property of HSC/MFs and, likely, of all hepatic 
MFs is the ability to migrate. This is an essential issue since it allows these MF-like cells to reach 
the site of injury and, as a part of the wound healing and pro-fibrogenic response, to align with 
nascent as well as already established fibrotic septa. Migration/chemotaxis of human HSC/MFs has 
been shown to be stimulated by a variety of mediators including polypeptide chemoattractant like 
PDGF-BB, monocyte chemoattractant protein 1 (MCP-1 or CCL2), angiotensin II, the two pro-
angiogenic cytokines VEGF and angiopoietin-1 as well as CXCR3 ligands (Pinzani and Marra, 2001; 
Novo et al., 2007; Parola et al., 2008; Mallat and Lotersztajn, 2013; Novo et al., 2014). Most of 
these peptides (in particular PDGF-BB, CCL2 and VEGF) operate by stimulating a Ras/ERK and 
JNK1/2 signalling in a redox- and NADPH oxidase - dependent manner (Novo et al., 2011). 
Interestingly, a raise in the intracellular levels of reactive oxygen species (as induced by defined 
compounds like menadione or 2,3-dimethoxy-1,4-naphtoquinone, or by exposure of cells to 
hypoxic conditions)  has been shown to be sufficient  to stimulate oriented migration of either 
HSC/MFs or even of MF-like cells derived from mesenchymal stem cells  by eliciting the same 
Ras/ERK and JNK1/2 signaling pathway (Novo et al., 2006a; Novo et al., 2011; Busletta et al., 2012; 
Novo et al., 2012). 
3.3.3 HSC/MFs as cells involved in ECM synthesis and remodeling.  According to current literature, 
fibrogenesis progression is mainly characterised by the replacement of the typical low-density 
basement membrane of the space of Disse with fibrillar matrix. In particular, this is believed to 
result primarily from an unbalance between excess deposition of fibrillar collagens (mainly 
collagen type I and III) as well as other ECM components and integrin ligands, and a 
reduced/altered degradation and remodeling of ECM itself (Pinzani and Marra, 2001; Friedman, 
2008a; Parola et al., 2008; Forbes and Parola, 2012; Mallat and Lotersztajn, 2013).  HSC/MFs, as 
major profibrogenic cells, have a prominent role in ECM deposition during CLDs in response mainly 
to the master profibrogenic cytokine TGFβ1 that, similar to what described for PDGF-BB, can be 
released by activated macrophages, activated/damaged LSECs or platelets as well as from fully 
activated HSC/MFs, once again as an autocrine/paracrine loop. In addition to TGFβ1, several other 
mediators of ECM excess deposition have been identified and the list include ROS and the major 
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aldehydic end-product of lipid peroxidation 4-hydroxynonenal (HNE) (Parola et al., 2008; Novo and 
Parola, 2008) as well as connective tissue growth factor (CTGF) and cannabinoids (Mallat and 
Lotersztajn, 2013). In relation to ECM remodeling, it has been shown in the past that HSC/MFs 
their ability to produce ECM-degrading enzymes according to the activation state; in their 
quiescent state HSCs produce metalloproteinases (MMPs), MMP activators able to cleave pro-
MMPs into their active form as well as specific tissue inhibitors of the metalloproteinases (TIMPs). 
In the early stage of activation HSCs can still produce MMPs and their activators but do not 
significantly express TIMPs. Of relevance, fully activated HSC/MFs behave as a phenotype 
expressing low levels of MMP-1 (interstitial collagenase) but, at the same time, high levels of 
MMP-2, MMP-9, MMP3 or Stromelysin, which are not really so efficient in degrading fibrillary 
matrix, as well as high levels of TIMP-1.  
3.3.4 HSC/MFs and their ability to contract. HSC/MFs, when activated, have been proposed to 
contribute to increased portal resistance during CLD fibrogenic progression. This contribution is 
believed to be reversible until the major cirrhosis related changes are developed, including the 
formation of thickened fibrotic septa and intrahepatic shunts as well as lobular distortion,  and the 
increase in portal pressure is fixed (Friedman, 2008a).  As already mentioned in a previous section, 
contractility in response to vasoactive mediators or and neurotransmitters of the ANS is a feature 
of quiescent HSCs (i.e., liver specific pericytes) which is emphasized even in earlier stages of 
fibrosis when activated HSCs start to express  contractile filaments including α-SMA and myosin 
(Rockey et al., 1992a; Saab et al., 2002) which, in turn, can generate those calcium-dependent and 
calcium-independent contractile forces contributing to cellular contractility (Bataller et al., 2001; 
Yee, 2001; Laleman et al., 2007). Similarly to what described for HSCs during regeneration (i.e., 
following partial hepatectomy or acute injury), HSC/MFs during chronic liver injury take contact 
with LSECs and contribute to angiogenesis, an essential event that is associated to fibrogenesis 
and CLD progression. In advanced cirrhosis HSC/MFs, which accumulate in large numbers, have 
been proposed to progressively impede portal blood flow, possibly with responses to vasoactive 
mediators and signaling pathways related to interaction with ECM that result either in the 
constriction of individual sinusoids or in the contraction of  the cirrhotic liver (Pinzani et al., 1992; 
Melton et al., 2006).  Contractility of HSC/MFs, which increase their density and coverage of 
sinusoidal lumen, is controlled mainly the opposite action of NO and ET-1 as well as by a number 
of additional mediators like angiotensin II, eicosanoids, carbon monoxide, somatostatin and atrial 
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natriuretic factor (Reynaert et al., 2002; Rockey, 2003; Friedman, 2008a). Of interest, HSC/MFs are 
likely to contribute (by their pro-angiogenic response, see later) to the progressive development of 
intrahepatic shunts (Friedman, 2008a; Novo et al., 2014).  
Extensive literature data indicate that conditions of chronic liver injury can lead to vascular 
disorder in which ET-1 is overproduced by HSCs whereas NO release by LSECs is reduced (Kawada 
et al., 1993; Geerts, 2001; Rockey, 2001; Friedman 2008; Iwakiri et al., 2014). Although ET-1 was 
originally identified as vasoconstrictor produced mainly by endothelial cells [Yanagisawa et al., 
1988), HSCs represent both a a major source as well as a target for ET-1 during liver injury (Kawada 
et al., 1995; Mallat et al., 1996; Pinzani et al., 1996;  Rockey and Weisiger, 1996). ET-1 has a 
prominent contractile effect on HSCs and MFs, which has been proposed to contribute to portal 
hypertension in the cirrhotic liver (Rockey et al., 1992b; Kawada et al., 1993; Kawada et al., 1995; 
Mallat et al., 1996; Pinzani et al., 1996; Rockey and Weisiger, 1996; Geerts, 2001; Friedman 2008a; 
Iwakiri et al., 2014). The scenario of interactions between LSECs and HSC/MFs is likely to be more 
complex in regulating intrahepatic vascular pathophysiology. Indeed, the LSEC phenotype  is 
presumably the  result of the action of several polypeptides, including VEGF angiopoietins, 
ephrins, and fibroblast growth factors (FGFs) but is also sensitive to mechanical forces like those 
due to shear stress: both pro-angiogenic polypeptides and shear stress can modulate endothelial 
NO synthase (eNOS) activity in LSECs, thereby regulating flow and vascular tone in the sinusoids 
[Shah et al., 1997].  LSECs can also affect the early response of HSCs by means of factors released 
in a paracrine way such as  the cellular isoform of fibronectin that, in turn,  can contribute to early 
HSC activation and, particularly, their synthesis of ET-1 (Jarnagin et al., 1994). However, ET-1 (that 
can stimulate proliferation of early-cultured HSCs) has been reported to inhibits fully activated 
HSC/MFs (Rockey et al., 1998). This is relevant in relation to the change of phenotype (i.e., 
capillarization) the LSEC undergo during chronic liver injury  which is associated with a reduction in 
eNOS activity and NO synthesis after injury, possibly because of post-translational de-regulation of 
eNOS (Iwakiri et al., 1914). Since NO is believed to maintain HSCs in a quiescent state, NO 
reduction can facilitate HSCs activation and contribute to switch on fibrogenic progression of CLDs 
(Langer et al., 2008; Deleve et al., 2008).  A final degree of complexity relies on the fact that during 
injury also HSCs have been reported to produce NO, likely following iNOS up-regulation in  
response to pro-inflammatory cytokines or endotoxemia (reviewed in Iwakiri et al., 2014). An 
overall interpretation of this complex scenario is that all these interactions are reasonably able to 
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facilitate remodeling and constriction of the sinusoidal vasculature, resulting in an increase of 
hepatic vascular resistance as an early feature of intrahepatic portal hypertension. 
 
3.4 HSC/MFs as cells involved in liver angiogenesis.   
 Fibrogenic progression of CLDs is associated to significant vascular remodeling affecting 
mainly liver sinusoids as well as to changes in the phenotype of LSECs and of their close 
interactions with activated HSC/MFs.  As it is well known, the LSECs lose their fenestrae and the 
space of Disse becomes the site of abnormal deposition of basement membrane matrix, a change 
overall defined as “capillarization” of sinusoids. These changes, according to what already 
mentioned in the previous section, are accompanied by  alterations in the reciprocal synthesis of 
NO and ET-1 between LSECs and HSC/MFs. Vascular remodeling also involves additional and pro-
angiogenic cross-talk between LSECs and HSC/MFs that are critical for CLD progression with 
several research groups envisaging liver pathological angiogenesis as an event facilitating 
fibrogenesis (Medina et al., 2004; Fernández et al., 2009; Novo et al., 2014; Iwakiri et al., 2014).    
LSECs in conditions of chronic injury can release PDGF, the most potent mitogenic and 
chemotactic stimulus for HSC/MFs and even offer a contribute to the synthesis of TGF-β1 (with 
activated macrophages and HSC/MFs being the major contributors) (Friedman, 2008a, 2008b; 
Parola et al., 2008; Mallat and Lotersztajn, 2013; Novo et al., 2014; Pellicoro et al., 2014; Iwakiri et 
al., 2014). The phenotype of LSECs is highly affected mainly by VEGF that under physiological 
conditions has been reported to modulate the size and number of LSECs fenestrae by operating 
through the receptor VEGFR1 (Shah et al., 1999; Funyu et al., 2001; Yokomori et al., 2003; May et 
al., 2011). This is relevant because introduces the essential role of hypoxia and hypoxia-inducible 
factors (HIFs) in sustaining liver pathological angiogenesis associated to the fibrogenic progression 
of CLD (Medina et al., 2004; Fernández et al., 2009; Novo et al., 2014; Iwakiri et al., 2014).  Indeed, 
the presence of hypoxic areas within chronically damaged liver parenchyma is very common and 
progressive during CLD development, with HIFs primarily involved in mediating the switch of pro-
angiogenic response (Rockey et al., 1998; Langer et al., 2008). Liver angiogenesis in CLD 
progression is closely  related to chronic activation of wound healing and histopathological 
changes occurring in liver parenchyma. Increased deposition of ECMs and formation of fibrotic 
septa, which are paralleled by vascular changes, are by themselves events favoring an impairment 
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of oxygen diffusion (Fernández et al., 2009; Novo et al., 2014; Iwakiri et al., 2014). During CLD both 
sprouting and intussusceptive angiogenesis are involved and have a role in the genesis of portal 
hypertension in both intra- and extrahepatic circulation (Iwakiri et al., 1914). Along these lines, 
elegant studies performed in conditional Notch1 knockout mice have outlined the critical role of 
Notch1 in LSECs for maintaining fenestration of LSECs, suggesting that  the loss of Notch1 can 
result in pathological angiogenesis, the development of nodular regenerative hyperplasia and 
portal hypertension in intrahepatic circulation (Radaeva et al., 2007). Histopathological analysis of 
cirrhotic livers by different laboratories has indeed indicated the significantly increased number of 
new vessels in fibrotic septa as well as around regenerative nodules (Medina et al., 2004). 
 As previously mentioned, hypoxia, angiogenesis and liver fibrogenesis are believed to be 
intrinsically correlated with both clinical studies on human patients and experimental rodent 
model of fibrosis indicating that angiogenesis and fibrogenesis develop in parallel. Moreover,  data 
from experimental studies employing antiangiogenic therapeutic strategies unequivocally indicate 
that these strategies are extremely effective in reducing fibrogenic progression, inflammatory 
infiltrate, the number of α-SMA positive MFs as well as the increase in portal pressure (Medina et 
al., 2004; Novo et al., 2007; Fernández et al., 2009; Moon et al., 2009; Valfrè di Bonzo et al., 2009; 
Novo et al., 2014; Novo et al., 2012; Iwakiri et al., 2014; Cannito et al., 2014). Along these lines, 
VEGF expression has been detected in hypoxic areas of chronically injured livers being limited to 
LSECs, hepatocytes and activated HSC/MFs  (Medina et al., 2004; Novo et al., 2007; Fernández et 
al., 2009; Valfrè di Bonzo et al., 2009; Novo et al., 2014; Iwakiri et al., 2014; Cannito et al., 2014). 
This means of course that HSC/MFs and likely all MF-like cells can be modulated in their  behavior 
by proangiogenic cytokines released by hypoxic hepatocytes LSECs and, in an additional 
autocrine/paracrine loop, also by profibrogenic cells themselves. Indeed human and rodent 
HSC/MFs have been shown to respond to hypoxia  by expressing VEGF-A and angiopoietin 1 as 
well as their related receptors  VEGFR2 and Tie-2, in CLDs (Novo et al., 2007; Taura et al., 2008; 
Choi et al., 2010). At the same time, one should consider that HSC/MFs are also critical cellular 
target for the action of VEGF and angiopoietin I.  VEGF has been shown to stimulate in HSC/MFs 
proliferation and increased deposition of extracellular matrix as well as increased migration and 
chemotaxis (Novo et al., 2007,2012). In addition,  HSC/MFs oriented migration has been reported 
to just require the exposure to hypoxic conditions (Novo et al., 2012). Our group has outlined that 
hypoxia- or VEGF stimulated oriented migration of human HSC/MFs relies on a biphasic 
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mechanism that requires: i) an early phase that is switched on by ROS released either by 
mitochondria under hypoxic conditions or through ligand-receptor related activation of 
NADPHoxidase (following ligand receptor interaction), resulting in redox-dependent activation of 
Ras/ERK and JNKs; ii) a late and delayed phase of oriented migration depending on HIF-1α-
mediated, ROS-stabilized, upregulation of VEGF expression which, in turn, can operate as 
autocrine/paracrine chemoattractant when released extracellularly (Novo et al., 2011,2012). 
These data offer a rational explanation for images collected by immunohistochemical analysis 
designed to investigate HIFs and major hypoxia-sensitive gene targets  like VEGF, VEGFR2, 
angiopoietin I and Tie2 and performed on human and rodent fibrotic/cirrhotic liver. These data led 
to the hypothesis that hypoxia, through HIF-mediated pathways, may affect the migration of MF-
like cells and their proangiogenic behavior, leading these cells to align with developing septa and 
then drive both fibrogenesis and angiogenic response (Novo et al., 2007,2012,2014; Fernández et 
al., 2009). 
3.5 HSC/MFs interact with cells of innate immunity: pro-fibrogenic and pro-resolution issues 
          According to the definition of cells at the crossroad of relevant pathophysiological events,  
HSC/MFs are involved during CLD in a critical cross-talk with inflammatory cells, particularly cells 
of innate immunity like Kupffer cells and macrophages of extrahepatic origin as well as natural 
killer (NK) and natural killer T (NKT) cells. These interactions are of extreme interest because they 
can either sustain CLD fibrogenic progression as well as to facilitate resolution of fibrosis.  
Activated Kupffer cells indeed can release a complex panel of mediators which includes 
pro-inflammatory cytokines like tumor necrosis factor-α (TNF), interleukin 1 (IL-1), IL-6, IL-10, and 
IL-18 as well as several chemokines such as macrophage chemotactic protein-1 (MCP-1, CCL2), 
macrophage inflammatory protein 2 (MIP-2, CXCL2), RANTES (CCL5 or regulated on activation, 
normal T cell expressed and secreted), macrophage inflammatory protein (MIP)-1α (CCL3) and -1β 
(CCL4) (Friedman, 2008a; Smith, 2013; Tacke and Zimmermann, 2014; Marra and Tacke, 2014). 
Activated Kupffer cells also release other polypeptides like osteopontin, PDGF and TGFβ1 but also  
reactive oxygen species (ROS). Of course in the chronic liver injury scenario most of these 
mediators are mainly intended to sustain and/or modulate the inflammatory response by 
sustaining the infiltration of inflammatory cells into the liver and modulating wound healing 
response. However, apart from what already described for PDGF, TGFβ1 and ROS, HSC/MFs 
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respond also to CCL2 (oriented-migration) which is indeed a prominent chemokine during the 
progression of CLDs being also actively synthetized and released by fully activated HSC/MFs in 
another relevant autocrine/paracrine loop  (Pinzani and Marra, 2001; Parola et al., 2008; Marra 
and Tacke, 2014).  Literature indicated that HSC/MFs  upon activation by TLR4 ligands or other 
stimuli, represent a very significant additional source of CCL2 and critically sustain monocyte 
recruitment in chronically injured livers. This is relevant since the number of Kupffer cells seems to 
decrease during inflammation and fibrogenesis whereas the number of monocyte-derived pro-
fibrogenic macrophages (designated as  CD11b+F4/80+) has been found to increase in inflamed 
liver (Duffield et al., 2005). Indeed, CCL2 seems to play a major role during CLD fibrogenic 
progression by significantly contributing to the recruitment into injured liver of inflammatory 
monocytes leading to the so-defined population of pro-inflammatory and pro-fibrogenic 
macrophages which, in a study employing tracking of the glycoprotein Ly6C (marker of circulating 
monocytes) have been identified as Gri+Ly6Chi macrophages (Karlmark et al., 2009). These Gri+Ly6hi  
macrophages, in addition to the conventional role in sustaining inflammatory response and further 
hepatocyte injury, are in turn those involved in regulating the classic phenotypic responses of 
HSC/MFs by favoring the process of HSC activation/transdifferentiation (Tacke and Zimmermann, 
2014). These pro-inflammatory and pro-fibrogenic macrophages are different from those defined 
as pro-resolution macrophages (Ly6Clow) that originate in response of mediators from hepatic MFs 
or other hepatic cells such as CX3CL1. Ly6low macrophages, which are typically involved in the 
removal of cell debris and pro-fibrogenic signals, express and release TRAIL and MMP9, that can 
promote apoptosis of MFs,  as well as matrix metalloproteases such as MMP12 and MMP13 that 
can efficiently degrade/remodel ECM (Fallowfield et al., 2007; Ramachandran et al., 2012). Of 
relevance, Ly6Clow macrophages are apparently derived from a phenotypic transition of the 
profibrogenic Ly6Chi macrophages and characterized by evidence of prior phagocytosis of dying 
cells (Ramachandran et al., 2012). Interestingly, removal of etiology or efficient therapy can then 
either favor apoptosis of HSC/MFs and/or result in a prominent role of pro-resolution 
macrophages, potentially leading to fibrosis reversal (Schuppan and Pinzani, 2012; Mallat and 
Lotersztajn, 2013; Schuppan and Kim, 2013; Novo et al., 2014). Indeed, regression of liver fibrosis 
(evident in experimental rodent models of fibrosis but also described, at least in pre-cirrhotic 
stage, in human livers)  involves four major aspects that are the regeneration of hepatocytes, the 
reversal of HSC/MFs to the vitamin A-storing quiescent phenotype, the removal of MFs by 
apoptosis and, finally, the lysis of ECMs.         
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 Along these lines, and in addition to the role of pro-resolution macrophages, one should 
also take in mind that  liver fibrosis regression requires the removal of HSC/MFs and, more 
generally, of hepatic MFs from fibrotic septa. This can happen either following reversal of 
HSC/MFs towards a more quiescent phenotype, as shown in a murine model of liver injury 
(Troeger et al., 2012), or through the induction of HSC/MFs apoptosis which is facilitated by the 
fact that these cells can express CD95, TNF receptor 1, p75 and TRAIL receptors (Iredale et al., 
1998; Wright et al., 2001; Kendall et al., 2009). It should be stressed once again that both these 
events (phenotype reversal and apoptosis) can occur when the etiological condition has been 
discontinued (typical in murine models of fibrosis) or therapy is efficient (in both murine models 
and human conditions) since HSC/MFs during CLD progression are typically set to a resistant, anti-
apoptotic and NF-kB – related phenotype (Novo et al., 2006b; Oakley et al., 2009; Iredale et al., 
2013). A third possible mechanism potentially able to favor removal of HSC/MFs  relies on their 
senescence. Indeed, an elegant study has shown that hepatic MFs can undergo senescence, with 
senescent MFs being characterized by a block of proliferation, down-regulation of the expression 
of ECM proteins and up-regulation of the expression of matrix degrading enzymes (Krizhanovsky 
et al., 2008). In the same study, senescent MFs have been shown to be then cleared from the site 
of injury by the intervention of liver specific natural killer (NK) cells, usually located in the sinusoids 
at close proximity to liver non-parenchymal cells. These NK cells (abundant and having a rapid 
turn-over being substituted by bone marrow-derived cells), which increase enormously in relation 
to chronic viral infection and/or chronic inflammation, are able to selectively kill early activated 
HSC but not quiescent or fully activated and MF-like cells (Gao and Radaeva, 2013). This because 
during the process of activation/transdifferentiation early activated HSCs produce and release 
retinoic acid which, in turn, can upregulate on transient HSCs the expression of NK cell activating 
ligand retinoic acid inducible gene 1 (RAE1). Since transiently activated HSCs overexpress on their 
surface TRAIL receptors (Taimr et al., 2003), RAE1 by binding to NKG2D on NK cells can lead to NK 
cell activation resulting in the death of HSCs through  TRAIL- and NKG2D dependent mechanisms 
(Radaeva et al., 2006). Fully activated HSC/MFs have lost retinol stores and can not produce any 
more retinoic acid or RAE1 and for this reason are then resistant to the action of NK cells.  NK-
mediated killing of human HSCs can also depend on the expression by HSCs of the NK cell 
activating receptor NKp46 (Gur et al., 2012) as well as by the fact that activated HSCs apparently 
have lost the ability to express MHC-1 antigen (i.e., able to suppress NK cell function) (Melhem et 
al., 2006; Muhanna et al., 2011). A number of elegant studies has also provided evidence that 
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activated NK cells, through the release of interferon-γ  (IFN-γ  ), can induce HSCs cell cycle arrest 
ad apoptosis (Rockey et al., 1992b; Melhem et al., 2006)  as well as to enhance their intrinsic 
ability to kill activated HSCs (Radaeva et al., 2006).   
3.6 HSC/MFs and interactions with cells of the adaptive immunity.  
T lymphocytes are believed to contribute to the modulation of liver fibrogenesis by means 
of their interactions with either pro-fibrogenic cells and/or other cells  of innate and adaptive 
immunity. Th1 and Th2 lymphocytes have been proposed to differently affect fibrogenic 
progression of CLDs as suggested by data from liver fibrosis studies performed on different strains 
of mice. By using the same murine model of liver fibrosis C57BL/6 mice, in which Th1 response is 
known to predominate, display a weaker fibrotic reaction than BALB/c mice, the latter model 
displaying the predominance of  Th2 response  (Shi et al., 1997). This can suggest that Th1 cells, 
through typical cytokines like IL-12 and IFN-γ  may act by limiting or inhibiting liver fibrogenesis 
(Pellicoro et al., 2014; Muhanna et al., 2008; Wynn et al., 1995). IFN-γ can suppress collagen 
deposition by regulating the balance of MMPs and TIMPs expression and, together IL-12, can also 
negatively affect the expression and release of pro-fibrogenic cytokines by Th2 cells (Wynn, 2004). 
Concerning Th2 lymphocytes, the proposed predominant profibrogenic action, shown in the 
experimental models by Schistosoma spp. (Wynn et al., 1995), is believed to rely mainly on the 
ability of these lymphocytes to release IL-13 (Pellicoro et al., 2014; Wynn, 2004). IL-13 can up-
regulate TGF-β1 and MMP9 expression as well as  promote fibrogenesis by controlling on MFs the 
relative expression of IL-13 receptor α1 (IL-13Rα1) versus  the related decoy receptor IL-13Rα2 
(Wynn, 2004; Chiaramonte et al., 1999).   
The role of the Th1/Th2 paradigm in regulating liver fibrogenesis has been clarified  by 
studies investigating the role of Th17 and cells regulatory T (Treg) cells, the latter being a  subset 
of CD4+ T helper cells expressing CD25 and able to release the anti-inflammatory and 
immunosuppressive cytokine IL-10.  Treg cells have been shown to strongly increase in the liver of 
patients affected by chronic HCV infection, primary biliary cirrhosis and other autoimmune liver 
diseases (Pellicoro et al., 2014) and depletion of these cells has been reported to exacerbate 
fibrosis in the rat BDL model (Katz et al., 2011). Moreover, Treg cells have been proposed to 
depress fibrogenesis in the Schistosoma spp.-induced fibrosis through their ability to specifically 
suppress Th2 cells (Turner et al., 2011). In addition,  in primary human HSCs, Tregs were found to 
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upregulate the expression of typical pro-fibrogenic genes like TGF-β1, α-SMA, procollagen type I, 
CCL2, TIMP1, and MMP2 in an IL-8-dependent manner (Langhans et al., 2013). 
Whether  Th17 cells are concerned,  these cells are known to increase in number both in 
the serum and the liver of  patients affected by several forms of either acute or chronic liver injury 
as well as to release, when activated, both IL-17 and IL-22. The putative pro-fibrogenic role of IL-17 
relies on the knowledge that IL-17 receptor, in particular, is expressed by HSCs, monocytes, 
Kupffer cells as well as cholangiocytes. HSCs respond to IL-17 by upregulating collagen type I by 
involving  activation of the STAT3 signaling pathway, but IL-17 is also known to upregulate 
expression of other mediators like IL-1β, IL-6, TNF-α and TGF-β in target cells (Meng et al., 2012). 
 
 
4. Portal fibroblasts as a source of portal MFs   
 Portal fibroblasts are liver resident fibroblasts located in the portal tract mesenchyme that 
surrounds bile ducts  that can be easily detected since, unlike HSCs,  they express several specific 
markers like fibulin 2, elastin, IL-6, cofilin 1 and the ecto-ATPase nucleoside triphosphate 
diphosphohydrolase-2 (NTPD2) (Dranoff and Wells, 2010; Wells, 2014). As mentioned in a previous 
section, portal fibroblasts have been proposed to be able to give raise to α-SMA positive MFs 
defined as portal MFs, as also reproduced in vitro when portal fibroblasts are cultured on plastic or 
glass (Dranoff and Wells, 2010; Forbes and Parola, 2011; Iwasaiko et al., 2012; Mallat and 
Lotersztajn, 2013; Lemoinne et al., 2013; Wells, 2014). However, it should be noted that at least in 
theory  portal MFs may also originate also from other sources, including vascular smooth muscle 
cells of the wall of hepatic artery or portal vein (Dranoff and Wells, 2010). Portal MFs have been 
suggested to primarily act as pro-fibrogenic cells in conditions of biliary fibrosis, likely together 
with activated HSC/MFs (Kinnmann and Housset, 2002; Dranoff and Wells, 2010; Wells, 2014).  In 
particular, it has been proposed that portal fibroblasts and portal MFs are the first cells responding 
to bile duct ligation (BDL, an experimental model of secondary biliary cirrhosis), with HSCs and 
then HSC/MFs migrating later at the site of biliary injury (Kinnmann and Housset, 2002). The same 
group went further in suggesting that HSCs and portal fibroblasts may occupy different niches, 
with the HSCs niche being induced by hypoxia during injury and portal fibroblasts niche by the 
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ductular reaction (Lemoinne et al., 2013). According to this interpretation, HSC/MFs may mediate 
liver wound healing whereas portal MFs may regulate scar formation.  
Indeed, from an historical point of view, a first evidence for the origin of portal MFs was 
obtained using the BDL  model in which portal fibroblasts were shown to  proliferate immediately 
after surgical intervention to give raise to a population of desmin-negative, α-SMA-positive cells 
adjacent to proliferating bile ducts and connective tissue stroma (Tuchweber et al., 1996; 
Beaussier et al., 1997). Similar data were obtained in another study in precision-cut liver slices 
where cells resembling portal fibroblasts, not HSCs, proliferated following exposure to bile acids 
(Clouzeau-Girard et al., 2006). Moreover, several in vivo and in vitro data (the latter obtained by 
employing primary culture of isolated portal fibroblasts, undergoing activation/differentiation to 
MF-like cells) support the hypothesis of transition of portal fibroblasts into portal MFs having the 
ability to produce and secrete fibrillary collagen (types I, III and IV) (reviewed in Dranoff and Wells, 
2010; Wells, 2014).            
 The involvement of portal MFs, as originated by portal fibroblasts,  in biliary fibrosis has 
been somewhat challenged, at least from a quantitative point of view, by a recent and already 
previously cited fate tracing study (Mederacke et al., 2013). These Authors developed a transgenic 
mice carrying a bacterial artificial chromosome with a Cre reporter driven by lecithin-retinol 
acyltransferase in which more than 99% of HSCs were reported to be specifically and efficiently 
labeled. In this study, overall suggesting HSCs as the major cell source of MF-like cells in CLDs 
irrespective of etiology, data related to the model of biliary fibrosis indicated in any case the 
involvement of an aliquot of MFs not derived from HSCs, likely then originated from portal 
fibroblasts.  However (see Wells, 2014), although the study was nicely performed, the possibility 
exists that, due to technical limitations of the transgenic model employed, the real involvement of 
MFs derived from portal fibroblasts may have been underestimated.  In addition, as also indirectly 
suggested by data from the fate tracing study, it has been proposed that portal MFs may have a 
role as contractile cells also in conditions in which predominate the pattern of bridging fibrosis. As 
suggested by Wells in a nice recent and detailed review on portal fibroblast and portal MFs   
(Wells, 2014) this may be relevant and plausible if one consider that  bridging fibrosis connects 
fibroblast-rich regions such as the portal tract and the central vein.  
If we come back to biliary fibrosis, the primary role of portal fibroblasts and portal MFs is 
supported by the knowledge that the injury to cholangiocytes is believed to represent a 
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prerequisite for the diffentiation of portal fibroblasts into portal MFs. The hypothesis (summarized 
in Figure 5) is here that once damaged, cholangiocytes acquire the ability to express and release 
TGFβ2 (Wells et al., 2004) as well as other relevant mediators like PDGF-BB, IL-6, CCL2 and 
connective tissue growth factor (CTGF). These mediators are likely responsible for the activation 
and differentiation of portal fibroblasts into portal MFs, also considering that portal fibroblasts are 
known to express the receptors for these polypeptide factors (Dranoff and Wells, 2010). This may 
be followed by an autocrine perpetuation by portal MFs not dissimilar from what reported for 
HSC/MFs. Accordingly, the strict interactions between portal MFs and activated/damaged 
cholangiocytes may also significantly contribute to CLD progression in other clinical setting, 
particularly those characterized by bridging fibrosis. Indeed, several laboratories have outlined the 
existence of a direct relationships between the intensity of the  ductular reaction (a definition that 
applies to a  peculiar form of hyperplastic response of cholangiocytes in pathological conditions) 
and the severity of ECM deposition in either animal models as well as human liver diseases of 
different etiologies, including chronic HCV and NAFLD/NASH (Clouston et al., 2005; Fabris et al., 
2007; Richardson et al., 2007;  Lorenzini et al., 2010). To this scenario one should ideally add 
concepts related to the possible involvement, particularly in pathophysiological conditions, of the 
so-called  population of bi-potent hepatic progenitor cells (HPCs). As nicely reviewed by Wells, 
there are report from literature suggesting that portal fibroblasts may be actively involved in the 
peribiliary stem cell niche in either fetal development as well as during liver regeneration and 
repair in CLD (Wells, 2014), in an overall CLD scenario in which Wnt or Notch signaling modulate 
lineage differentiation of HPCs towards hepatocytes or cholangiocytes and Hedgehog signaling 
may be involved in the interactions between mesenchymal cells in the portal tract and epithelial 
cells (Omenetti et al., 2007; Boulter et al., 2012). As a matter of fact, HPCs have been reported to 
be surrounded by portal fibroblasts in injured livers (Greenbaum et al., 2011) and portal MFs have 
been proposed to secrete ECM required for progenitor cell expansion (Van Hul et al., 2009). 
 
5. Bone marrow – derived MFs   
The interest in bone marrow - derived cells as extrahepatic cells able to engraft injured 
liver initiated historically with studies designed in order to evaluate the possibility to employ these 
cells in terms of regenerative medicine (i.e., repopulation of liver parenchyma following an injury).  
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The original suggestion was that bone marrow - derived stem cells (BMdSCs) could 
transdifferentiate into either hepatocytes and cholangiocytes. Overall these specific attempts  
were unsatisfying and it was recognized that that in fact there is little if any contribution of the BM 
stem cell compartment to epithelial cells, with few positive results being  possibly artefacts or 
even the result of cell fusion between BMdSCs and hepatocytes (reviewed in Newsome and 
Forbes, 2012). However, in one of these pioneer studies a laboratory noticed that MF-like cells in 
human livers were positive for markers that could only derive from bone marrow - derived cells 
recruited in liver parenchyma, as was the case of MFs carrying Y chromosome found in the liver of 
females that received previously a bone marrow transplant from male donors (Forbes et al., 2004).  
In a decade in which regenerative medicine was exploding, with several clinical studies trying to 
use bone marrow derived cells also in the field of hepatology (Houlihan and Newsome, 2008) the 
concept that these cells may give raise to fibrogenic cells was of course potentially a bad news.  In 
the following years a number of studies have been performed to investigate this issue and the first 
one confirmed the existence of the problem since mice transplanted with traceable bone marrow 
cells (GFP positive) showed the presence of GFP positive stellate cells in their liver (Baba et al., 
2004). Other studies employing the transplant of either murine or human BMdSCs showed a 
significant increase in the flux of bone marrow - derived MFs  in the progression of chronic  liver 
injury (Russo et al., 2006; Asawa et al., 2007; Valfrè di Bonzo, 2008; Fujimiya et al., 2009). Two of 
these studies proposed that bone marrow - derived mesenchymal stem cells were the most 
relevant population able to give raise to MFs (Russo et al., 2006; Valfrè di Bonzo et al., 2008). A 
further study reported  the involvement of α-SMA negative bone marrow - derived  cells defined 
as fibrocytes able to engraft injured livers and to contribute to liver fibrogenesis (Kisseleva et al., 
2006). Studies performed on human liver specimens confirmed the hypothesis of MFs derived 
from bone marrow cells although the proportion of these cells was variable and usually 
representing a minority of the overall population of hepatic MFs (Forbes et al., 2004; Dalakas et 
al., 2010). At present this concept is the prevailing one: hepatic MFs from bone marrow cells can 
be found in either experimental or clinical conditions but their contribution is believed to be quite 
limited (Forbes and Parola, 2011; Newsome and Forbes, 2012). It is correct to mention that a study 
has questioned whether bone marrow cells may actually contribute to ECM deposition in any 
significant amount in the liver (Higashiyama et al., 2009). Properly designed experimental studies 
using modern lineage tracing experiments and reporter systems are required to finally clarify this 
issue. 
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 6. MFs from hepatocytes and cholangiocytes ?    
  Literature from the last decade has offered several studies suggesting that pro-fibrogenic 
cells may originate, in addition to HSCs, portal fibroblasts and bone marrow - derived cells, also 
from either hepatocytes or cholangiocytes through a process of epithelial to mesenchymal 
transition or EMT (Choi et al., 2009; Cannito et al., 2010, Xie and Diehl, 2013; Novo et al., 2014). 
The term EMT conventionally refers to a critical biologic process, originally described in embryonic 
development, in which cells of epithelial origin undergo a phenotypic and functional transition 
towards the acquisition of a mesenchymal phenotype (i.e., by losing polarization and specialized 
junctional structures as well as by undergoing cytoskeletal reorganization) and related properties. 
In particular, the EMT process leads these cells to acquire the ability to migrate and to produce 
and secrete ECM components (Kalluri et al., 2009; Cannito et al., 2010). The involvement of EMT 
as a mechanism contributing to liver fibrosis was first proposed, following homologous studies in 
the field of renal and lung fibrosis, by a series of studies that initially showed the ability of either 
hepatocytes and cholangiocyte to undergo a transition to a fibroblastoid/mesenchymal-like 
morphology when exposed to TGFβ1 (reviewed in Kalluri et al., 2009; Cannito et al., 2010). In 
these experiments classic EMT changes  were detected (E-cadherin down-regulation, acquisition of 
mesenchymal markers like vimentin, desmin, α-SMA and the protein S100A4, also known as 
fibroblast-specific protein 1 or FSP-1).         
 The first relevant study investigating the role of EMT of hepatocytes employed 
AlbCre.R26RstoplacZ double transgenic mice submitted to the chronic carbon tetrachloride (CCl4) 
model (Zeisberg et al., 2007). The involvement of EMT in liver fibrogenesis was inferred by two 
order of data: first, when fibrosis was established approx. 15% of hepatic cells were found to be 
positive for FSP-1 expression, with 5% of cells co-expressing FSP-1 and albumin; second, inhibition 
of liver fibrosis and putative EMT-derived fibroblasts/MFs were significantly inhibited by 
treatment with bone morphogenetic protein-7 (BMP-7), a protein known to efficiently antagonize 
TGFβ1 signaling; these  data, in particular, were homologous to those obtained in a parallel study 
using transgenic mouse over-expressing Smad7 in hepatocytes (Dooley et al., 2008). Evidence for 
some EMT-related changes were reported in the same study by analyses performed on liver 
specimens from patients affected by chronic HBV infection (Dooley et al., 2008).    
 Even more impressive were initial experimental and clinical reports in which EMT of 
cholangiocytes was suggested  as putative pro-fibrogenic mechanism. These studies, mainly 
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related to conditions of biliary fibrosis, offered images of cholangiocytes  apparently co-expressing 
α-SMA and cytokeratin 19 (CK19, a marker expressed by both adult cholangiocytes and HPCs) (Xia 
et al., 2006). The laboratory of Anna Mae Diehl produced several studies performed using the rat 
or murine BDL model of secondary biliary fibrosis (reviewed in Choi et al., 2009). These studies 
proposed a cause-effect relationships between EMT of cholangiocytes appearance of portal MFs 
and then biliary fibrosis as well as  a major role for the Hedgehog signaling pathway. Of relevance, 
EMT-related changes for cholangiocytes as well as the relevance of Hedgehog signaling were also 
reported  in human patients affected by primary biliary cirrhosis (PBC), by primary sclerosing 
cholangitis (PSC), or biliary atresia (Choi et al., 2009; Cannito et al., 2010). Additional mechanistic 
studies also proposed a critical role in EMT and liver fibrogenesis for Notch signaling on the basis 
of results from experiments based on the use of a specific c-secretase inhibitor or of neutralizing 
antibody against Jagged 1 (Chen et al., 2012; Liu et al., 2012; Xie et al., 2013). Because of the 
potential impact of these studies, different research laboratories became involved in investigating 
the role of EMT and starting from 2010 at least four elegant fate tracing studies, performed using 
properly designed triple transgenic mice, significantly challenged  the real pro-fibrogenic relevance 
of EMT of either hepatocytes or cholangiocytes. A first study from David Brenner group employed 
a very complex transgenic model (triple transgenic mice expressing ROSA26 stop beta-
galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) green fluorescent protein or GFP) 
designed to trace hepatocyte-derived cells (labeled by beta-gal) and pro-fibrogenic cells (GFP 
labeled) (Taura et al., 2010). The conclusions from this study were straightforward: Authors could 
not find cells positive for both GFP and beta-gal, then apparently excluding origin of profibrogenic 
cells from hepatocytes. The same research group used the Cre/LoxP system in order to follow the 
cell fate of CK19 positive cells (i.e., cholangiocytes) in CK-19(YFP) or FSP-1(YFP) transgenic mice 
that were then subjected to BDL or  chronic CCl4 treatment (Scholten et al., 2010). Once again 
results were unequivocal in indicating that cholangiocytes were not expressing EMT markers and 
that cells positive for FSP-1(YFP) were negative for CK19. In a third study, the same group reported 
that FSP-1, a putative and widely used EMT marker, was not expressed by pro-fibrogenic and 
collagen type I producing cells. Moreover,  FSP-1 positive cells in chronically injured livers were not 
co-expressing the typical markers of MFs like α-SMA and desmin but rather F4/80 and other 
markers of cells belonging to the myeloid-monocytic lineage, suggesting that FSP-1 cells may 
represent a subset of macrophages involved in CLD progression differing from Kupffer cells 
(Österreicher et al., 2011). A fourth study, this time from the group of Rebecca Wells, employed 
29 
 
 
the Cre/LoxP system to obtain transgenic mice designed to follow the fate of cells expressing 
alpha-fetoprotein (AFP), that is a way to label any hepatocyte and cholangiocyte since these cells 
derive all from AFP-positive precursors (Chu et al., 2011). These mice were then submitted to 
different experimental model of fibrosis and Authors reported that MFs were always AFP negative, 
then excluding an origin from either hepatocytes or cholangiocytes. These studies (Taura et al., 
2010; Sholten et al., 2010; Österreicher et al., 2011; Chu et al., 2011) and others here not cited as 
well as the recent study from the Robert Schwabe laboratory (Mederacke et al., 2013) suggesting 
that HSCs are by far the major cell source of hepatic MFs, irrespective of etiology, strongly indicate 
that the involvement of EMT as pro-fibrogenic mechanism is highly controversial and, in case, of 
very minor relevance.  
 
 
 
7. MFs and pro-fibrogenic mechanisms:  implications for CLDs in terms of pattern of fibrosis and 
etiology 
 In this final section we will take advantage of the actual knowledge concerning the origin of 
MFs as well as of the established and emerging pro-fibrogenic mechanisms in order to offer in the 
end a synthetic view of how these concepts may impact the progression of CLD in terms of pattern 
of fibrosis with a reference to the specific etiology of the disease.     
 Indeed, an overall analysis of literature data clearly suggests that the specific etiology of a 
CLD is relevant in relation to CLD progression. The view we are going to offer is in line with the 
original proposal from Pinzani and Rombouts  (Pinzani and Rombouts, 2004),  as refined more 
recently (Parola et al., 2008; Novo et al., 2014). This view identifies four well defined and distinct 
patterns of fibrosis development that can be correlated to specific etiologies, prevailing pro-
fibrogenic mechanisms and the type(s) of hepatic MFs involved. In this final section we will just 
mention the more relevant pro-fibrogenic mechanisms and the interested reader can refer to 
recent  and exhaustive reviews for more details (Mallat and Lotersztajn, 2013; Novo et al., 2014).   
7.1 Post-necrotic or bridging fibrosis 
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This is pattern that is typically observed in liver specimens from patients affected by 
chronic viral (HBV, HCV) infection or by an autoimmune disease. The pattern of bridging fibrosis is 
characterized by the predominant formation of fibrotic septa connecting portal areas with 
centrilobular vein  (i.e., portal-central septa), which represent the consequence of portal-central 
bridging necrosis. This pattern is typically associated with the so-called interface hepatitis, as well 
as with the formation of blind septa or fibrotic septa connecting different portal areas in 
chronically damaged liver parenchyma. This is a pattern that leads to an early involvement of 
centrilobular vein, with formation of neo-vessels (i.e., angiogenesis) and of porto-central shunting. 
The prevalent fibrogenic mechanism proposed to be associated to this pattern and the related 
etiologies is represented by chronic activation of wound healing with a significant contribution of 
oxidative stress.  According to current literature data fibrogenic progression is here provided 
mainly by HSC/MFs and portal MFs, with a possible minor contribution of MFs originated from 
bone marrow - derived cells.    
 
 
7.2 Pericellular or perisinusoidal fibrosis 
This peculiar pattern of fibrosis is also sometimes referred to as chicken-wire fibrosis and is 
mainly detected in liver specimens from patients with either alcoholic steatohepatitis (ASH) or 
suffering of metabolic derangements such as those affected by non-alcoholic fatty liver disease 
(NAFLD) progressing towards non-alcoholic steatohepatitis (NASH). A similar pattern  has been 
detected also in the liver of patients with hemochromatosis. Excess deposition of ECM is found in 
the space of Disse and is usually proposed as the consequence of the activation of peri-sinusoidal 
HSCs to HSC/MFs.  This pattern results in the previously mentioned capillarization of sinusoids that 
in the natural history of these diseases precedes the formation of fibrotic septa with a pattern of  
fibrosis development that progressively tends to connect cetrilobular vein areas to portal areas.   
The prevailing pro-fibrogenic mechanism in this pattern of fibrosis is represented by oxidative 
stress with a significant contribution, particularly in conditions of NASH, by lipotoxicity.  
7.3 Biliary fibrosis 
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This pattern of fibrosis is observed in PBC and secondary biliary cirrhosis as well as in PSC 
and is characterized by the typical formation of fibrotic septa connecting portal areas  and  
surrounding nodular areas of liver parenchyma. This is a rather peculiar pattern of fibrosis which 
develops by preserving rather normal connection between centrilobular vein and portal tracts and 
is typically associated to the so-called ductular reaction, that is an intense proliferation of reactive 
bile ductules and periductular MFs. In these conditions of chronic biliary damage, as previously 
mentioned, periductular MFs are believed to derive from portal fibroblasts as well as, in a later 
phase, from HSCs. The derangement of normal interactions between cholangiocytes, portal 
fibroblasts and, possibly, HPCs, is believed to predominate as pro-fibrogenic mechanism with an 
additional role played by oxidative stress.  
7.3 Centrilobular fibrosis 
This pattern of advanced fibrosis is unrelated to CLDs and is typically a secondary scenario 
found in conditions characterized by venous outflow obstruction, as is the case in patients affected 
by heart failure.  In these clinical settings ECM deposition results in the formation of fibrotic septa 
connecting central vein areas (central-central septa) leading to the unique feature defined as 
reversed lobulation.  
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Figure 1. Major pathophysiological events involved in the fibrogenic progression of CLDs. The 
involvement of pathophysiological events is referred to the natural history of a typical disease 
(irrespective of etiology) starting from early injury and initial fibrosis, then leading to the 
development of vascular changes and tissue architecture derangement characteristic of liver 
cirrhosis and finally involving the development of portal hypertension and other complications, 
hepatic failure and hepatocellular carcinoma.   
Figure 2. Cross-talk between hepatic cell populations in liver fibrogenesis. Liver fibrogenesis, 
irrespective of etiology, is a dynamic process sustained and modulated by an intense cross talk 
occurring between different hepatic cell populations, resident or recruited into chronically injured 
liver. These interactions involve the synthesis and release of several mediators, including growth 
factors, cytokines, chemokines, adipokines, ROS and vasoactive agents and plasma proteins, with 
functional responses of hepatic cells being also significantly modulated by conditions of hypoxia.    
Figure 3. Liver Mesenchymal cells: from embryo development to liver diseases. The scheme 
illustrates actual knowledge on liver mesenchymal cells in normal and pathological conditions. 
Liver mesenchymal cells in the normal adult liver (middle panel) are proposed to originate from 
mesothelial cells deriving from the septum transversum mesenchyme (STM) during embryo 
development (left panel). HSCs originate from a population of sub-mesothelial cells (possibly also 
directly from STM) from which also originate perivascular mesenchymal cells (PMCs) that then 
give raise to portal fibroblasts, smooth muscle cells and fibroblasts around the centrilobular vein. 
Right panel offer the current literature view of hepatic myofibroblasts as a heterogeneous cell 
population originating from HSCs, portal fibroblasts and, to a less extent, bone marrow-derived 
cells. The origin of MFs throught epithelial-to-mesenchymal transition of hepatocytes or 
cholangiocytes is at present controversial.      
Figure 4. The process of activation and trans-differentiation of HSCs into activated and MF-like 
cells (HSC/MFs). The process of activation and trans-differentiation of HSCs into HSC/MFs involves 
two major steps: i) the initiation step, potentially reversible, leading to a transiently activated 
phenotype, able to proliferate and critically involved in the resolution of parenchymal injury; if the 
injury is acute, these cells undergo either apoptosis or reversion to the quiescent phenotype; ii) 
the perpetuation step, in which the pro-fibrogenic environment and related mediators sustain a 
trans-differentiation of cells to a fully activated pro-fibrogenic phenotype that, with its functional 
responses, is critical in promoting the progression of the disease; removal of the etiology or 
efficient therapeutic approach can potentially lead to resolution of fibrosis associated to HSC/MFs 
senescence or apoptosis.    
Figure 5.  Activation of portal fibroblasts and bone marrow - derived cells. Portal fibroblasts, that 
can be recognized in vivo on the basis of their expression of a number of characteristic markers, 
are proposed to undergo a process of activation towards portal MFs that is essentially sustained 
by mediators expressed and released by damaged or activated cholangiocytes during the course of 
chronic injury affecting the biliary tree and leading to biliary-like fibrosis. Portal MFs are α-SMA 
positive cells but their positivity to other markers (like those of portal fibroblasts) may be not so 
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selective. In some pathophysiological conditions a relatively limited amount of activated MFs may 
originate from bone marrow - derived cells, like either mesenchymal stem cells (MSC) or 
fibrocytes, which are recruited into chronically injured liver by a restricted number of mediators 
(with a major role attributed to SDF-1) in a way which is also modulated by parenchymal hypoxia.   
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